Breast cancer following curative chemotherapy for non-Hodgkin's lymphoma and the effect of drug resistance proteins to the final outcome. A retrospective study

Journal of B.U.ON.

Volumn 10, Issue 1, 2005, Pages 71-76

  Tsavaris, Nicolas ^a   Kosmas, C ^a   Kavantzas, N ^a   Lazaris, A ^a   Skopelitis, E ^a   Dimitrakopoulos, A ^a   Siakantaris, M P ^a   Papalambros, E ^a   Diamantis, N ^a   Patsouris, E ^a   Pangalis, G A ^a  

^a IASO GENERAL HOSPITAL   (Greece)

Author keywords

Breast cancer; Drug resistance related proteins; LRP; MRP; Non Hodgkin's lymphoma; Pgp

Indexed keywords

AMINOGLUTETHIMIDE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; GLYCOPROTEIN P; LETROZOLE; LUNG RESISTANCE PROTEIN; MEGESTROL ACETATE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PACLITAXEL; PREDNISONE; STEROID RECEPTOR; TAMOXIFEN; TRASTUZUMAB; VINBLASTINE; VINCRISTINE SULFATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; BREAST CARCINOGENESIS; CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY;

EID: 24944500351     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bhatia S, Robison LL, Oberlin O et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996; 334: 745-751.
2. Cutuli B, Dhermain F, Borel C et al. Breast cancer in patients treated for Hodgkin's disease: clinical and pathological analysis of 76 cases in 63 patients. Eur J Cancer 1997; 33: 2315-2320.
3. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster ovary cells in vitro: Cross-resistance, radioautographic and cytogenetic studies. Cancer Res 1970; 30: 1174-1184.
4. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 1996; 192: 768-780.
5. Scheper RJ, Broxterman HJ, Scheffer GL, Meijer CJ, Pinedo HM. Drug transport protein in clinical multidrug resistance. Clin Chim Acta 1992; 206: 25-32.
6. Plumb J, Kaye SB. The cell membrane and drug resistance. Cancer Topics 1986; 6: 30-34.
7. Kim R. Expression of the multidrug resistance gene in human tumors. Hiroshima J Med Sci 1990; 39: 71-77.
8. Crathorn AR, Roberts JJ. Mechanism of the cytotoxic action of alkylating agents in mammalian cells and evidence for the removal of the alkylated groups from deoxyribonucleic acid. Nature 1966; 211: 150-153.
9. Shustik C, Dalton W, Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 1995; 16: 1-78.
10. Cole SPC, Bhardwaj G, Gerlach JH et al. Overexpression of a transport gene in a multidrug resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
11. Scheper RJ, Broxterman HJ, Scheffer GL et al. Overexpression of a Mr 110.000 vesicular protein in non-P glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475-1479.
12. Schlaifer D, Laurent G, Chittal S et al. Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumor and stromal cells of human cancers. Br J Cancer 1990; 62: 177-182.
13. Nooter K, Westerman AM, Flens MJ et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995; 1: 1301-1310.
14. Lizquierdo MA, Scheffer GL, Flens MJ et al. Broad distribution of the multidrug resistance related vault lung resistance protein in normal human tissues and tumors. Am J Clin Pathol 1996; 148: 877-887.
15. Alexander D, Yamamoto T, Kato S, Kasai S. Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today 1999; 29: 401-406.
16. Johnstone A, Thorpe R (eds). Immunohistochemistry in Practice (2nd edn). London, Blackwell Scientific Publ, 1987, pp 261-289.
17. Cobleigh M, Vogel C, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
18. Dixon WJ, Massey FJ Jr (eds). Introduction to statistical analysis (4th edn). New York, McGraw-Hill, 1983.
19. Hancock SL, Tucher MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993; 85: 25-31.
20. Bradshaw DM, Arcesi RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998; 16: 3674-3690.
21. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J. Clin Oncol 1999; 17: 1061-1070.
22. Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L, Silingardi V. Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 1977; 44: 185-192.
23. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol 1997; 34 (Suppl 5): 9-19.
24. Ellis PA, Smith IE, Detre S et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998; 48: 107-116.